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Background:  The  variability  of  terms  and  deﬁnitions  of Adverse  Events  Following  Immunization  (AEFI)
represents  a  missed  opportunity  for optimal  monitoring  of  safety  of immunization  in pregnancy.  In  2014,
the Brighton  Collaboration  Foundation  and  the World  Health  Organization  (WHO)  collaborated  to  address
this  gap.
Methods:  Two  Brighton  Collaboration  interdisciplinary  taskforces  were  formed.  A  landscape  analysis
included:  (1)  a  systematic  literature  review  of  adverse  event  deﬁnitions  used  in  vaccine  studies  dur-
ing  pregnancy;  (2)  a worldwide  stakeholder  survey  of  available  terms  and  deﬁnitions;  (3) and  a  series  of
taskforce  meetings.  Based  on  available  evidence,  taskforces  proposed  key terms  and  concept  deﬁnitions
to  be  reﬁned,  prioritized,  and  endorsed  by a global  expert  consultation  convened  by WHO  in Geneva,
Switzerland  in  July 2014.
Results:  Using  pre-speciﬁed  criteria,  45  maternal  and  62  fetal/neonatal  events  were  prioritized,  and  key
terms and  concept  deﬁnitions  were  endorsed.  In  addition  recommendations  to  further  improve  safety
monitoring  of immunization  in  pregnancy  programs  were  speciﬁed.  This  includes  elaboration  of  disease
concepts  into  standardized  case  deﬁnitions  with  sufﬁcient  applicability  and  positive  predictive  value  to
be  of  use for monitoring  the  safety  of  immunization  in pregnancy  globally,  as well as  the  development
of  guidance,  tools,  and  datasets  in support  of  a globally  concerted  approach.
Conclusions:  There  is  a need  to improve  the safety  monitoring  of immunization  in  pregnancy  programs.  A
consensus  list  of terms  and  concept  deﬁnitions  of  key  events  for  monitoring  immunization  in  pregnancy
is  available.  Immediate  actions  to further  strengthen  monitoring  of  immunization  in pregnancy  programs
are identiﬁed  and  recommended.
ublis©  2015  The  Authors.  P
. IntroductionThe concept of maternal immunization – vaccinating pregnant
omen in order to protect women themselves and their newborn
nfants from serious infectious diseases – emerged along with the
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development of the ﬁrst vaccines in the early 20th Century [1]. Rou-
tine vaccination of pregnant women with tetanus toxoid has been
successfully implemented worldwide since the 1960s for the pre-
vention of maternal–neonatal tetanus [2]. In some countries, the
recognition of severe inﬂuenza disease in pregnant women has led
to the recommendation to vaccinate women  with inﬂuenza vaccine
[3,4]. The resurgence of pertussis disease in the United States and
the United Kingdom has led those countries to recommend vaccina-
tion of pregnant women to prevent pertussis in infants [5,6]. Since
the 1980s, the United States National Institutes of Health (NIH)
has funded clinical studies of vaccines in pregnancy [7]. World-
wide, studies evaluating the safety, immunogenicity, and efﬁcacy of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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arious licensed and investigational vaccines in pregnancy against
nﬂuenza, tetanus, Haemophilus inﬂuenzae type b, pneumococcus,
eningococcus, group B streptococcus (GBS), Bordetella pertussis
nd respiratory syncytial virus (RSV) have been completed or are
nderway [7].
Although many studies and surveillance systems have collected
nformation on reported adverse events following immunization
AEFI) in both mothers and their infants, there is variability in the
erms and deﬁnitions of the events observed and assessed for a
otential causal association. Since 2000, the Brighton Collabora-
ion (BC), an independent professional network with the mission
o enhance the science of vaccine research by providing standard-
zed, validated objective methods for monitoring safety proﬁles
nd beneﬁt–risk ratios of vaccines has provided investigators with
ase deﬁnitions of AEFI [8]. In 2004, the Brighton Collaboration was
equested by WHO  to develop a guidance document harmonizing
afety assessment during maternal and neonatal vaccine trials. This
ocument has been updated repeatedly in response to the rapidly
volving ﬁeld [9]. In 2011, the NIH convened a series of meetings of
xperts with the goal of producing guidance to researchers in the
eld of maternal immunization, including recommendations con-
erning adverse events [10–14]. These NIH guidance documents
ere designed with high resource settings in mind, where research
n maternal vaccines mostly had been conducted. Further attention
o maternal immunization has been given by WHO  which recently
ecommended that pregnant women receive inﬂuenza and pertus-
is vaccination under certain circumstances [15–17]. Highlighting
he urgency and need for tools to standardize assessment of vaccine
afety in pregnancy in all resource settings, large studies of vaccines
or pregnant women, against inﬂuenza, pertussis, GBS, and RSV are
ow being planned or implemented in low- and middle- income
ountries [7,18,19].
No consensus vaccine safety monitoring guidelines or adverse
vent deﬁnitions to meet the need of concerted safety monitoring
uring the life cycle (development and post-licensure monitoring)
f vaccines for global access in rapidly emerging immunization in
regnancy programs exist. This report describes the process pur-
ued by BC and the WHO  Initiative for Vaccine Research to advance
he development of these necessary vaccine safety monitoring
ools.
. Methods
In 2014, Brighton Collaboration, together with WHO, con-
ened two taskforces to conduct a landscape analysis of current
ractice, available terms, and case deﬁnitions and to develop and to
ropose interim terminology and concept deﬁnitions for the eval-
ation of the safety of vaccines administered to pregnant women.
ne taskforce reviewed maternal and obstetric events, and the
ther reviewed fetal and newborn events. Taskforce member-
hip reﬂected diverse geographic and professional backgrounds, as
ell as broad expertise in clinical research, epidemiology, regu-
atory and immunization implementation requirements, maternal
mmunization, obstetrics, and pediatrics. Members represented
cademia, the pharmaceutical industry, regulatory agencies, clini-
al investigators, private and public organizations. The taskforces
athered relevant information from a systematic review of pub-
ished literature on the safety of vaccination during pregnancy in
others and infants as well as from a global stakeholder survey of
elevant terms and safety assessment methods.
The objective of the systematic literature review was to deter-ine the extent and variability in AEFI deﬁnitions and reporting
n maternal immunization studies. The methods and results of the
eview were reported separately [20]. The objective of the global
takeholder survey was to identify existing case deﬁnitions of key3 (2015) 6441–6452
events in pregnant women and newborns, as well as to describe
existing methods for the assessment of safety of vaccines used in
pregnancy. We  developed an expansive list of national and inter-
national obstetric and pediatric professional societies, government
agencies, regulatory agencies, research institutions, local and inter-
national organizations, and pharmaceutical companies that could
be involved in work relevant to our objectives. We  sent each insti-
tution an electronic survey and asked them to describe activities
that collected information on key events during pregnancy and
the newborn period. We  also searched for information in exist-
ing standard terminology criteria documents, healthcare databases,
population-based surveys, pregnancy registries, active and passive
surveillance reporting systems, meeting and study reports, ongo-
ing interventional and non-interventional studies, and the Brighton
Collaboration network of vaccine safety experts. Through these
efforts, we established an inventory of stakeholders and a repos-
itory of existing adverse event terms, case deﬁnitions, protocols,
practice guidelines, and manuscripts with data pertinent to the
assessment of safety of vaccines in pregnant women  and their
infants. The taskforces held regular meetings to deﬁne procedures,
to review progress of information gathering, to prioritize event
terms, and to recommend deﬁnitions of terms for further review
at a larger expert consultation.
The taskforces identiﬁed “key terms”—deﬁned as the most
important adverse event terms based on frequency of occurrence,
severity or seriousness, public health relevance, potential for pub-
lic concern, and measurability or comparability with existing data.
Key terms were organized with their synonyms (if pertinent), and
existing deﬁnitions with bibliographic sources. When a taskforce
identiﬁed more than one existing deﬁnition, it proposed a best
deﬁnition based expert assessment of deﬁnition applicability and
positive predictive value. These key terms, synonyms, and proposed
deﬁnitions were presented at the expert consultation for further
discussion.
The expert consultation took place at WHO  in Geneva,
Switzerland, July 24–25, 2014 and it included taskforce participants
and other invited experts [21]. The objectives of the consulta-
tion were: (1) to review existing relevant obstetrical and pediatric
adverse event case deﬁnitions and guidance documents; (2) to
prioritize terms for key events for continuous monitoring of immu-
nization safety in pregnancy; (3) to develop concept deﬁnitions for
these events; and (4) to recommend a core data set of key terms of
events to be collected when monitoring the safety of immunization
in pregnancy. The terms and deﬁnitions were intended to be used
speciﬁcally in vaccine safety monitoring. They were not intended
to be used for diagnosis or treatment of patients, nor in non-vaccine
clinical epidemiologic studies.
The taskforces proposed key terms and concept deﬁnitions. For
each term, the full consultation determined whether the term was
important for the assessment of safety of vaccines in pregnancy
(i.e. was  a “key term”), identiﬁed potential synonyms, determined
whether there was  consensus agreement on concept deﬁnitions,
and considered the applicability of the term and concept deﬁnitions
in different resource settings. This led to a list of key terms with
synonyms and short descriptions of the respective disease concept,
recognizing that this was a ﬁrst critical step towards globally har-
monized safety monitoring. It was acknowledged that an approach
to reducing misclassiﬁcation of reported events and to promoting
data comparability in globally concerted safety monitoring would
require more elaborate standardized case deﬁnitions. Such deﬁni-
tions should allow the classiﬁcation of events based on objective, as
well as measurable criteria at different levels of diagnostic certainty
to serve the needs of monitoring the safety in diverse cultural and
resource settings during the vaccine life cycle. Selected key terms
were further classiﬁed as “priority outcomes” if they were consid-
ered to be the most important terms for the assessment of safety
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f the vaccine in pregnancy, “outcomes” if there were considered
mportant but not critical, and “enabling” if the term was used to
ssist in the assessment of other outcomes or priority outcomes.
Overall, for organizational and reporting purposes, key terms
ere classiﬁed in broad conceptual categories. Key terms for the
afety assessment related to immunization of pregnant women
ere sub-classiﬁed as: pregnancy-related, complications of preg-
ancy, complications of labor and delivery, and maternal health
erms. Key terms for the assessment of safety in the fetus
nd newborn were sub-classiﬁed as: events of delivery, physi-
al examination and anthropometric measurements, and neonatal
omplications classiﬁed by organ system.
. Results
.1. Systematic literature review of adverse event deﬁnitions
The results of the systematic literature review are reported in
etail separately [20]. Brieﬂy, among 74 studies included in the
eview, 10 were clinical trials, 54 were observational studies, and
0 were reviews. Most studies were related to inﬂuenza vaccine,
ollowed by yellow fever vaccines, and then Tdap. A total of 240
ifferent types of AEFI were reported on in these studies. Of these,
30 were systemic and 10 were injection site reactions. Consider-
ble variability of the event terms used and lack of consensus on
he deﬁnitions used for the assessment of AEFI reported in immu-
ization in pregnancy studies was identiﬁed, rendering meaningful
eta-analysis or comparison between studies and products chal-
enging.
.2. Stakeholder survey
WHO  contacted 446 individuals, and Brighton Collaboration
ontacted 500 individuals. Overall, 41% of individuals responded,
nd 40% of institutions responded. Individuals represented 427
nstitutions, of which 57% were based in the EURO and PAHO WHO
egions. Of the institutions that responded, 81% were from the
URO and PAHO WHO  regions (Fig. 1). Respondents conﬁrmed
he lack of standardized deﬁnitions for the assessment of safety
f vaccines in pregnant women and reported their adverse event
eporting to be based on classiﬁcations of events and terms used
or various medical purposes or developed for use in a given
rganization of research network. Individuals shared the actual
ase deﬁnitions, protocols, and manuscripts used, when available.
he survey identiﬁed relevant information from a wide variety of
roups, including Brighton Collaboration documents on safety of
accines, WHO  documents addressing vaccine safety and surveil-
ance of AEFI [9,22–26], the National Institutes of Health Toxicity3 (2015) 6441–6452 6443
Tables, publications and studies [10–14,27,28], the US  National
Children Study project [29–31], the Global Alliance on Prevention
of Prematurity (GAPPS) [32], reports from GAVI Alliance, UNICEF
and WHO  [33–40], established terminology databases including
the International Classiﬁcation of Diseases (ICD-9, ICD-10) [41,42],
Common Terminology Criteria for Adverse Events (CTCAE) [43],
Medical Dictionary for Regulatory Activities (MedDRA) [44] and
pregnancy and birth defect registries and guidance documents
[45–55], vaccine safety and pharmacovigilance surveillance sys-
tems including the CIOMS report on vaccine pharmacovigilance
[56], vaccine safety active surveillance programs [57–60], the
American College of Obstetrics and Gynecology (ACOG) practice
guidelines [61,62], investigators of current and planned clinical tri-
als, and the pharmaceutical industry working on candidate vaccines
for pregnant women.
3.3. Key terms and consensus deﬁnitions
Based on the ﬁndings of the landscape analysis and predeﬁned
criteria as described above, a total of 45 key terms describing med-
ical events of signiﬁcance for the assessment of safety of vaccines
in pregnant women  were identiﬁed by the maternal and obstet-
ric event taskforce. A total of 62 key terms were identiﬁed by the
neonatal and fetal event taskforce. The participants of the con-
sultation recommended the elaboration of disease concepts into
standardized case deﬁnitions with sufﬁcient applicability and pos-
itive predictive value to be of use for monitoring the safety of
immunization in pregnancy globally. Overall, 39 key terms were
reviewed, prioritized and agreed upon by the participants of the
consultation and consensus concept deﬁnitions were endorsed
for immediate use. A summary of all key terms are described
in Tables 1 and 2, respectively. A complete repository including
additional suggested terms and interim concept deﬁnitions sug-
gested by the taskforces is available at the Brighton Collaboration
website [63].
3.4. Other recommendations
In addition, the expert consultation identiﬁed and recom-
mended critical steps to further improve safety monitoring of
immunization in pregnancy programs (Table 3), including the
development of guidance for data collection, analysis and presen-
tation of safety data; tools for harmonized data collection, classi-
ﬁcation, and data sharing; and globally concerted secondary use
of health care datasets to strengthen active surveillance to enable
evidence based local and global response to safety concerns [20].
4. Discussion
We conducted a literature review, global stakeholder survey,
and expert consultation to assess key events related to safety mon-
itoring of immunization in pregnancy. We  identiﬁed substantial
heterogeneity of event deﬁnitions and assessment methods in cur-
rent practice, and described a structured approach to initiating
globally concerted action towards the ascertainment of the safety of
mothers and their children following immunization in pregnancy.
The systematic literature review was a hallmark of this con-
sensus process, highlighting the opportunities for improvement.
The strengths and limitations of this effort are discussed in detail
elsewhere [20]. The ﬁndings directly informed decision making
and prioritization both at the taskforce and consultancy levels,
and provide a useful baseline assessment for monitoring and re-
evaluation of globally concerted actions in this rapidly evolving
ﬁeld of research.
The stakeholder survey was the second hallmark of consensus
formation. Given the thorough approach, we interpret the response
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Table 1
Maternal key terms and concept deﬁnitions.
Term/synonyms Concept deﬁnition Prioritization
Pregnancy related terms
Pregnancy Period from when the woman misses her last normal menstrual period (ﬁrst day of last menstrual period plus
two  weeks), to the onset of labor/elective caesarian section or abortion (WHO)
Taskforce key term
Diagnosis of pregnancy Absence of menses combined with ultrasound documentation of pregnancy or physical examination
documenting enlarged uterus with detection of fetal heart beat
Note: Absence of menstruation with conﬁrmation by urine or serum test for presence of Beta-human
chorionic gonadotropin (B-HCG) is presumptive evidence for pregnancy
Taskforce key term
Gestational age
estimate*
S: Dating of
Pregnancy
Duration of
pregnancy
Dating of pregnancy from the ﬁrst day of the last menstrual period (LMP) with conﬁrmation by (in order of
most  to least accurate dating):
1st trimester ultrasound
1st trimester examination consistent with LMP
detection of fetal heart beat consistent with LMP and uterine size
2nd trimester ultrasound
3rd trimester ultrasound
Examination of the fetus
OR
Known date of fertilization (e.g. Assisted Reproductive Technology (ART), Intrauterine Insemination (IUI))
Enabling term
Trimesters Divisions of pregnancy into 3 parts that roughly correspond with maternal physiologic and fetal development
phases.
1.  NCS/NICHD divisions
1st: ≤12 weeks
2nd: 13–26 weeks from LMP
3rd: 27–40 weeks from LMP
2. WHO  divisions
1st: <4 mo or <16 weeks
2nd: 4–6 mo  or 16–28 weeks
3rd: 7–9 mo or 29–40 weeks
Taskforce key term
Term  pregnancy* A gestation of 37–41 6/7 weeks or 259 to 294 days in duration (NCS) Outcome
Antenatal care Care for the woman  and fetus during pregnancy (WHO) Taskforce key term
Post-partum care Care of the woman from delivery of placenta to 42 days after delivery (WHO) Taskforce key term
Peri-partum period Interval between delivery after 20 weeks gestation and 28 days after delivery Taskforce key term
Puerperium 4–6 weeks period of time following delivery Taskforce key term
Complications of pregnancy
Abortion*
S: Pregnancy Loss
Miscarriage
Pregnancy loss before 22 weeks of gestation
Note: Deﬁnition of fetal viability varies in different resource settings: 20–22 weeks in high resource versus 28
weeks in LMIC resource settings and corresponding fetal weight of 500 g vs 1000 g
Categories
Spontaneous: Pregnancy loss happens without any preceding intervention
Elective: Intervention (medicine or procedure) leads to pregnancy loss
Early: ≤12 weeks (ACOG) or <14 weeks (WHO)
Late: 13–22 weeks
Complete: All products of conception pass from uterus
Incomplete: Products of conception remain in uterus (Retained products of conception)
Threatened: First trimester bleeding
Outcome
In  utero fetal demise
(IUFD)
Death of a fetus in utero
Early fetal death: <14 weeks
Late fetal death: 14 to <20 or 22 weeks
Taskforce key term
Labor* Regular uterine contractions AND cervical change. Changes in the cervix include effacement (thinning) and
dilation (opening).
Enabling term
Preterm Labor*
S: premature labor
Labor prior to 37 weeks gestation
Note: Contractions without cervical change is NOT preterm labor
Priority outcome
Pre-eclampsia*
S: Toxemia
HTN in pregnancy
A pregnancy-related disorder characterized by an increase in the blood pressure after the 20th week of
gestation, and up to 6 weeks post-partum, combined with other abnormalities. (NCS)
Blood pressure ≥140 systolic or ≥90 diastolic on two  occasions at least 4 h apart after 20 weeks of gestation in
a  woman with previously normal blood pressures and protein in urine, OR Blood pressure ≥160 systolic or
≥110 diastolic twice in a short time interval
PLUS
Proteinuria >300 mg of protein in 24 h (or this amount extrapolated from a timed collection)
OR  Protein/Creatinine ratio > 0.3 OR 1+ in urine dip
OR
Elevated BP with onset of any of: Platelets <100,000, Serum Creatinine >1.1 OR a doubling of serum Creatinine,
OR  Liver transaminases twice normal (ACOG)
Priority outcome
Pre-eclampsia with
severe features*
S: Severe
preeclampsia
Severe toxemia
Pregnancy related disorder of severe hypertension and/or some other abnormalities (NCS)
Pre-eclampsia associated with any of the following ﬁndings: (ACOG)
(1) thrombocytopenia (platelets less than 100,000 per microliter)
(2) impaired liver function
(3) twice normal elevation of hepatic transaminases
(4) severe, persistent right upper quadrant or epigastric pain)
(5) progressive renal insufﬁciency (serum creatinine greater than 1.1 mg/dL or doubling of baseline in the
absence of other renal disease)
(6) pulmonary edema
(7) new-onset cerebral or visual disturbances
Priority outcome
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Table  1 (Continued)
Term/synonyms Concept deﬁnition Prioritization
Eclampsia*
S: seizure of
pregnancy
In a woman with pre-eclampsia, a convulsion that cannot be attributed to another cause. (NCS) Priority outcome
HELLP  Syndrome Variant of pre-eclampsia/eclampsia characterized by hemolytic anemia, elevated liver enzymes and low
platelet count
Taskforce key term
Gestational
hypertension*
S: Pregnancy
associated or
induced
hypertension (PIH)
Blood pressure ≥140 systolic/≥90 diastolic that starts after 20 weeks of gestation (measured twice at least
20  min  apart AND absence of protein or other stigmata of preeclampsia)
Priority outcome
Chronic Hypertension
with superimposed
pre-eclampsia*
Pre-eclampsia in a woman with diagnosis of chronic hypertension Priority outcome
Hyperemesis
gravidarum
Severe, intractable vomiting during early pregnancy accompanied by hypovolemia, weight loss, and
electrolyte imbalances
Taskforce key term
Fetal  growth restriction*
S: IUGR
A fetus that does not grow beyond the 10th% of conventionally accepted size for gestational age (NCS)
Other reported criteria: fundal height 3 cm below the expected height between 24–38 weeks of gestation;
ultrasound measured abdominal circumference (AC) <10%, Estimated fetal weight (EFW) <10%, EFW <10%
with abnormal Doppler studies, or birthweight <2500
Priority outcome
Oligohydramnios Low amniotic ﬂuid in utero
Ultrasound diagnosis: Total amniotic ﬂuid index of ≤5 cm or single pocked ≤2 cm OR Total amniotic ﬂuid
<8  cm,  or smallest vertical pocket <2 cm
Taskforce key term
Gestational Diabetes
Mellitus*
S: Diabetes of
pregnancy
Women  with carbohydrate intolerance with onset during pregnancy
Diagnosis based on administration of glucose challenge test at 24–28 weeks gestation
Suggested outcome
Antenatal Bleeding* Vaginal bleeding during pregnancy. Different etiologies and consequences depending on trimester of gestation Suggested outcome
Placental Abruption*
S: Abruption
Partial or total placental detachment after 20 weeks gestation prior to delivery of the fetus Taskforce key term
AND
Suggested outcome
Complications of labor and delivery
Pre-labor rupture of
membranes (PROM)*
Spontaneous ruptured membranes at or after 37 weeks of gestation before the onset of labor Outcome
Preterm pre-labor
rupture of membranes
(PPROM)*
Spontaneous ruptured membranes prior to <37 weeks of gestation before the onset of labor Priority outcome
Duration of rupture of
membranes
Time interval between rupture of membranes and birth
12 h is considered “prolonged” by some
Taskforce key term
Preterm  delivery* Delivery before 37 weeks of gestation are completed (WHO/CDC)
Subgroups (WHO):
Moderate to late Preterm: 32 to <37 weeks
Very Preterm: 28 to <32 weeks
Extreme Preterm: <28 weeks (included under Very Preterm category in some WHO  deﬁnitions)
Outcome
Cesarean section (C/S)
delivery*
S: abdominal
delivery
Delivery of fetus via abdominal incision (laparotomy) and then uterine incision (hysterotomy) Enabling term
Fetal  distress* The presence of signs in a pregnant woman, before or during childbirth, that suggest that the fetus may  not be
well
1.  If electronic monitoring available:
Persistent category 2 tracing that does not improve with intervention or a category 3 tracing
2.  If only spot monitoring with fetoscope or Doppler available:
Fetal bradycardia or tachycardia after a minimum of 2 min  baseline assessment
Suggested outcome
Note: This is a
complex term that
needs further
discussion and
reﬁnement
Dysfunctional labor
S: Labor dystocia
Failure to progress
Arrest of dilatation
Prolonged time between labor beginning and delivery
OR
Uterine contractions (less than 3 in 10 min  or inadequate strength) that do not result in progressive cervical
dilation
Taskforce key term
Note: This is a
complex term that
needs further
discussion and
reﬁnement
FIRST  stage labor
dysfunction:
Prolonged Latent Phase of Labor (S: latent phase arrest; arrest of labor in the latent phase)
Prolonged time before reaching active phase of labor
Greater than 20 h in nulliparous women  and greater than 24 h in parous women
Arrest of labor in the active phase (S: prolonged active phase of labor; prolonged ﬁrst stage of labor; active
phase arrest)
Prolonged time between reaching active phase of labor and 2nd stage of labor
≥6 cm dilation with membrane rupture and one of the following: 4 h or more of adequate contractions (e.g.
>200 Montevideo units), ≥6 h of inadequate contractions and no cervical change
Taskforce key term
Note: This is a
complex term that
needs further
discussion and
reﬁnement
Second stage labor
dysfunction:
S: cephalopelvic
disproportion (CPD)
Prolonged time between complete dilation and delivery of the fetus (2nd stage)
For  Nullipara: >4 h with epidural, or >3 h without epidural
For Multipara: >2 h with epidural and >1 h without epidural
Arrest of descent
After complete dilatation, failure of the fetal presenting part to descend through the pelvis
Taskforce key term
Note: This is a
complex term that
needs further
discussion and
reﬁnement
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Table 1 (Continued)
Term/synonyms Concept deﬁnition Prioritization
Chorioamnionitis* Inﬂammation of membranes around the fetus
Inﬂammation of the fetal sac membranes, characterized by otherwise unexplained maternal fever (at or above
38  degrees C (100.4 F) with one of more of the following: uterine tenderness and/or irritability, leukocytosis,
fetal tachycardia, maternal tachycardia, or malodorous vaginal discharge. (NCS)
Suggested outcome
Post-partum
endometritis
S:  Puerperal
endometritis or
endomyometritis
Infection of the uterus in the postpartum period
Infection of the endometrium, decidua and/or myometrium occurring at any time between birth and 42 days
postpartum. (NCS)
Taskforce key term
Maternal Fever* Elevation of body temperature ≥38 ◦C Outcome
Maternal sepsis
S: Septicemia
Systemic inﬂammatory response to blood borne bacteria or viruses or their byproducts.
Clinical syndrome deﬁned by the presence of both infection and a systematic inﬂammatory response. (NCS)
Taskforce key term
Post-partum
hemorrhage*
Blood loss accompanied by signs and symptoms of hypovolemia in the ﬁrst 24 h following the birth process Priority outcome
Maternal death* Death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration
and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management, but
not  from accidental or incidental causes
Direct obstetric death:  death of the mother resulting from conditions or complications which are unique to
pregnancy and occur during the antepartum, intrapartum, or postpartum period.
Indirect obstetric death: A maternal death that is not directly due to obstetric cause (such as from previously
existing disease, or disease developing during pregnancy, labor, or the puerperium but that was not unique to
pregnancy.)
Late Maternal Death: Death of woman from direct or indirect causes more than 42 days but less than one year
after  termination of pregnancy
Priority outcome
Maternal health terms
Deep Vein Thrombosis
(DVT)
A blood clot (thrombus) in a deep vein, predominantly in the lower extremity but may  include the pelvis or
upper extremity. (NCS)
Suggested outcome
HIV  infection HIV detected by accepted test
Use WHO  deﬁnitions of HIV www.who.int/topics/hiv aids
Taskforce key term
and suggested
enabling term
Nutritional Status Pre-pregnant weight of mother
Obesity: Body mass index (BMI) ≥ 30
Underweight (lack of proper nutrition): BMI  < 18.5
Taskforce key term
Maternal chronic
hypertension*
Blood pressure > 140/90 before 20 weeks gestation or prior to pregnancy Enabling term
Other  maternal health Anemia during pregnancy, purpura, maternal cardiomyopathy, maternal seizures, maternal neurologic
disorders, autoimmune disorders
Suggested
outcomes
Other post-partum
events
Lactation, mastitis, uterine rupture Suggested
outcomes
Sources of Accepted Deﬁnitions: WHO: World Health Organization; NCS: National Children’s Study; NICHD: National Institute of Child Health and Human Development;
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sCOG: American Congress of Obstetrics and Gynecology; CDC: Center for Disease C
* BC-WHO Consultation consensus term.
ate and geographic distribution of responses to be reﬂective of
he actual availability of event terminologies, case deﬁnitions, and
uidance documents in the regions where most of the structured
esearch into the safety of drugs and vaccines administered during
regnancy have thus far been conducted. The expert consultation
ecommended efforts be made to increase involvement from low-
nd middle-income countries, particularly in Africa and Asia, as tri-
ls and immunization programs are increasingly occurring in these
egions.
WHO  and the Brighton Collaboration continue to monitor
merging case deﬁnitions and guidance documents, as well as vali-
ation efforts informing best practice and harmonization efforts for
pcoming vaccines and programs of immunization in pregnancy.
he authors recognize that despite the taskforces’ efforts to cap-
ure existing deﬁnitions for key safety events in pregnancy, it is
ikely we have not identiﬁed all deﬁnitions available or needed.
hus, we encourage readers to share available information not cap-
ured or adequately represented in this publication by contacting
he WHO  (VaccineResearch@who.int) and Brighton Collaboration
contact@brightoncollaboration.org).
While challenging, the development of a common language
hrough harmonized deﬁnitions will facilitate efforts in the
esearch and implementation of vaccines for maternal immu-
ization. The consistent use of deﬁnitions of key events related
o immunization in pregnancy will enhance comparability of
afety outcomes monitored during the vaccine life cycle from and Prevention.
pre-licensure to post-licensure clinical trials, as well as from obser-
vational studies.
Harmonization of terms, disease concepts and the development
of standardized case deﬁnitions of key events related to safety
monitoring of immunization in pregnancy is a challenging exer-
cise, speciﬁcally in view of the need for applicability in high-
and low-income settings and the multiple stakeholders involved.
We  employed a structured approach building on the recognized
standard Brighton Collaboration process [8] to arrive at interim
terminology and concept deﬁnitions for immediate use, while
planning for collaborative development and validation of stan-
dardized case deﬁnitions with investigators and stakeholders in
the near future. We recognize that the establishment of a core
set of terms, disease concepts, and deﬁnitions is an important
step towards this aim, while acknowledging that not all pertinent
events may  be identiﬁed and deﬁned in anticipation. However, with
an established network and processes among globally collaborat-
ing investigators, additional ad hoc deﬁnitions may be developed
rapidly as the need arises.
Therefore, an important aspect of this effort was  the broad
net that was  cast to identify relevant methods, terms, and deﬁ-
nitions available from all resource settings. The early involvement
and contributions by a large group of stakeholders with diverse
backgrounds and the global expertise within the taskforces and
in the consultation strengthened the harmonization process from
its inception. Broad representation and face-to-face discussion
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Table  2
Neonatal key terms and concept deﬁnitions.
Term/synonyms Concept deﬁnition Prioritization
Events of delivery
Live Birth*
S: Live born
Delivery of an infant, regardless of maturity or birth weight, as determined by the presence of a
heartbeat or spontaneous respirations or spontaneous movement
Enabling term or
outcome
Stillbirth*
S: Stillborn
Fetal Demise/Death
Deadborn
Delivery of a dead fetus after 22 weeks of gestation (WHO)
Categories:
- Early Stillbirth Delivery ≥22 weeks and/or >500 g
-  Late Stillbirth Delivery ≥28 weeks and/or >1000 g
Other commonly reported subgroups:
- Antepartum or during pregnancy or “macerated”
-  Intrapartum, deﬁned as no signs of life at delivery and more than 500 g or >22 weeks of gestation,
with intact skin and no signs of disintegration in utero. The death is assumed to have occurred in the
12  h before delivery and to be more likely due to an intrapartum event. Excludes babies with severe
congenital anomalies
Priority outcome
Perinatal death* Death of fetus at or after 22 weeks of gestation and/or neonate up to 1 week (7 days) after birth Priority outcome
Neonatal death* Death of a live newborn at any time from birth to 28 days of life, regardless of gestational age.
Subgroups:
Very early neonatal death: <24 h
Early neonatal death: birth to <7 days
Late neonatal death: 7 to <28 days
Priority outcome
Infant  death* Death of a live born occurring from birth until 12 months of age
Subgroup: post-neonatal death: occurs between 28 days and 1 year of life
Priority outcome
Term  birth* Birth at ≥37 weeks to <42 weeks of gestation Enabling term or
outcome
Preterm birth* Birth before 37 weeks of gestation are completed
Subgroups: (WHO)
Moderate to late Preterm: 32 to <37 weeks
Very Preterm: 28 to <32 weeks
Extreme Preterm: <28 weeks
Priority outcome
Early  term birth* Birth at 37 to <39 weeks of gestation Outcome
Post-term birth*
S: Post-mature birth
Birth on or after 42 weeks of gestation Outcome
Physical examination and anthropometric measurements
Low Apgar Scores* Score of less than 7 on a 10 point Apgar scale after 5 min  Outcome
Low  Birth Weight* Birth weight below the normal birth weight range of 2500 to 3999 g
Subgroups:
Low  birth weight (LBW): <2500 g
Very low birth weight (VLBW): <1500 g
Extremely low birth weight (ELBW):<1000 g
Priority outcome
High  birth weight*
S: Macrosomia
Birth weight ≥4000 g Outcome
Small  for Gestational Age
(SGA)*
S: IUGR = intrauterine
growth restriction
Birth weight <10% for infants of same gestational age and gender in same population Priority outcome
Large  for Gestational Age
(LGA)*
Birth weight >90% for infants of same gestational age in same population Outcome
Birth  length* Crown-foot length in cm assessed in relation to gestational age Enabling term
Microcephaly* Head circumference >2 Standard deviations below mean for gestational age, gender and ethnic origin Outcome
Macrocephaly* Head circumference >2 standard deviations above mean for gestational age, gender and ethnic origin Outcome
Congenital anomalies*
S: Birth defects
Malformations
Abnormalities of body structure or function that are present at birth and are of prenatal origin. (WHO)
MAJOR ANOMALIES
Those that require surgical/medical treatment, have serious adverse effects on health or development
(functional), or have signiﬁcant cosmetic impact.
MINOR ANOMALIES
Those that do not in themselves have serious medical, functional or cosmetic consequences for the
child.  Includes those found in association with major anomalies
Priority outcome
Neonatal conditions classiﬁed by organ system
Systemic conditions
Asphyxia* Insufﬁcient oxygen supply to organs at birth resulting from inadequate ventilation or perfusion Priority outcome
Fever* Elevated body temperature at or above 38 ◦C measured at least once (BC)a Outcome
Hypothermia Decreased body temperature below 36 ◦C Taskforce key term
Infection* Infection regardless if acquired in utero, intrapartum or in neonatal period
Congenital infection: Acquired in utero at any time of gestation and prior to delivery
Key Event: Infection caused by organism for which mother received vaccination during pregnancy
(vaccine associated or vaccine failure)
Priority outcome
Sepsis  Infection associated with cardiovascular collapse and systemic, multiorgan involvement.
Neonatal sepsis: Sepsis diagnosed in the ﬁrst 28 days of life.
Accepted Categories:
(WHO)
Early onset: <7 days of age
Late onset: 7-90 days of age
(NCS) Early onset: <72 h of life
Late onset: ≥72 h of life
Taskforce key term
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Table 2 (Continued)
Term/synonyms Concept deﬁnition Prioritization
Sudden infant death
syndrome*
S: SIDS, cot death
Sudden death of any child under 12 months of age which remains unexplained after
excluding other causes of death (BC)b
Priority outcome
Failure to thrive or growth
deﬁciency*
Inability to maintain expected growth rate over time, evaluated by plotting individual
weight gain and growth on standard growth charts for the population
Suggested outcome
and taskforce key
term
Respiratory tract
Respiratory distress* Increase in respiratory rate above normal range for age and labored breathing (nasal
ﬂaring, grunting, retractions, pallor and cyanosis or hypoxemia). May  be transient or
persistent
Suggested outcome
Transient tachypnea of
newborn
S: TTN
Respiratory distress beginning shortly after birth and usually resolving over 24–48 h or
within 3 days of delivery.
Usually associated with retained lung ﬂuid after delivery AND Cesarean section delivery
with or without labor in term or preterm infants usually >35 weeks of gestation
Taskforce key term
Meconium Aspiration
syndrome
S: MAS
Aspiration pneumonia
Respiratory distress syndrome associated with presence of meconium stained amniotic
ﬂuid  in the lungs during or before delivery.
Usually associated with fetal distress prior to and at the time of delivery in term or
post-term infants AND visual inspection of trachea and larger airways by endotracheal
intubation and suctioning to determine the presence of meconium stained amniotic ﬂuid
Taskforce key term
Respiratory distress
syndrome
S: RDS
Hyaline membrane
disease
Surfactant deﬁciency
syndrome
A respiratory syndrome in premature infants caused by developmental insufﬁciency of
surfactant production and structural immaturity in the lungs. Begins shortly after birth
and  is manifest by respiratory distress
Taskforce key term
Persistent pulmonary
hypertension of the
newborn
S: PPHN
Persistent fetal
circulation
Persistence of fetal circulatory pattern of right to left shunting through the patent ductus
arteriosus and foramen ovale after birth due to excessively high pulmonary vascular
resistance. Begins shortly after birth, usually within the ﬁrst 12 h of life, and is manifest by
respiratory distress AND hypoxemia that is unresponsive to 100% oxygen and out of
proportion with ﬁndings in chest X-ray. Usually occurs in term infants
Taskforce key term
Apnea* Cessation of breathing for 15 (or 20) s or more, or a shorter respiratory pause associated
with bradycardia, cyanosis or hypoxemia, pallor, and/or hypotonia. Should be
distinguished from periodic breathing
Suggested outcome
Pneumonia An inﬂammatory condition of the lung affecting primarily the alveoli. It is usually caused
by  infection with viruses or bacteria.
Key event: Infection caused by organism for which mother received vaccination during
pregnancy
Taskforce key term
Chronic  lung disease
S: Bronchopulmonary
dysplasia (BPD)
A chronic lung disorder characterized by inﬂammation and scarring in the lungs that is
most common among infants who  were born prematurely and result in need for
supplemental oxygen
Taskforce key term
Neurologic/neuromuscular
Neonatal Hypoxia*
S: Neonatal Asphyxia
Decreased arterial concentration of oxygen and insufﬁcient blood ﬂow to cells or organs to
maintain their normal function, particularly the central nervous system.
Related terms:
Asphyxia = insufﬁcient oxygen supply to organs due to poor ventilation or poor perfusion
Anoxia = complete lack of oxygen
Hypoxia = decreased arterial concentration of oxygen
Ischemia = insufﬁcient blood ﬂow to maintain normal organ function
Taskforce key Term
and
Suggested outcome
Neonatal Encephalopathy*
S: Birth Asphyxia
Perinatal Asphyxia
Injury to the central nervous system that occurs when there is insufﬁcient delivery of
oxygen or blood to all or part of the brain (NCS)
OR
A disturbance of neurological function manifested by difﬁculty initiation and maintaining
respiration, depression of tone and reﬂexes, abnormal level of consciousness and often
seizures.
1.  Due to intrapartum hypoxic insult
2.  Due to another cause
May  be mild, moderate or severe.
Assessed by clinical and laboratory ﬁndings including: 5 min  Apgar score of 0–3;
Respiratory distress and Acidosis (pH < 7.0); Altered tone, depressed level of
consciousness, seizures; Multiorgan involvement; Abnormal CNS imaging or EEG. May
result in neonatal death or permanent damage to the brain and other organs. May  be
associated with perinatal events, rarely to prenatal events
Priority outcome
and
Taskforce key term
Hypoxic  Ischemic
Encephalopathy*
S: HIE
A syndrome of abnormal neurological behavior in the neonate, which is frequently
associated with multi-system dysfunction and follows severe injury before or during
delivery, associated with hypoxic and/or ischemic event.
May  be mild, moderate or severe.
Comment: The term Neonatal Encephalopathy, specifying if it is associated with
intrapartum event, is preferred
Priority outcome
and
Taskforce key term
Lethargy Reduced responsiveness to environmental stimuli Taskforce key term
Irritability* Abnormal responsiveness to stimuli or physiologic arousal, may  be in response to pain,
fright, a drug, emotional situation or a medical condition (CTCAE)
Suggested outcome
F.M. Munoz et al. / Vaccine 33 (2015) 6441–6452 6449
Table  2 (Continued)
Term/synonyms Concept deﬁnition Prioritization
Seizure*
S: Convulsion
Witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic–clonic, or
atonic motor manifestations (BC)c
Suggested outcome
Hypotonia/hypertonia Decreased or increased muscular tone for gestational and post-natal age Taskforce key term
Hyporreﬂexia/hyperreﬂexia Decreased or increased reﬂexes for gestational and post-natal age Taskforce key term
Meningitis Inﬂammatory process of the meninges (BC)d Taskforce key term
Meningoencephalitis Inﬂammatory process of the meninges and brain parenchyma (BC)e Taskforce key term
Intracranial
intraventricular
hemorrhage
S:  IVH
Bleeding in the ventricles or brain parenchyma
Associated with prematurity or other factors such as trauma, RDS, hypoxia–ischaemia,
hypo- or hypertension, other maternal and fetal factors.
Taskforce key term
Periventricular
leucomalacia
S:  PVL
Decreased perfusion, periventricular hemorrhage and/or necrosis in the periventricular
white matter and/or white matter, Associated with prematurity and IVH,
hypoxia-ischemia, other maternal and fetal factors
Taskforce key term
Sleeping  issues* Disturbance in sleep pattern Suggested outcome
Neurodevelopmental
disability*
Alteration in progression or regression of normal development of motor, speech or
cognitive skills as expected for gestational and post-natal age
Assessed by medical history, physical examination, and standard screening and
assessment tools appropriate for age. Serial assessment required due to variability in
individual acquisition of skills. Assessment at or beyond 1 year of age more likely to
represent true disability
Suggested outcome
Cardiovascular
Tachycardia/
Bradycardia*
Heart rate above or below normal range for age and gestational age Suggested enabling
term
Hypertension/
Hypotension
Blood pressure above or below normal range for age, gestational age, gender and length
and height
Taskforce key term
Heart  failure Cardiac dysfunction resulting in symptoms Taskforce key term
Hematologic
Bleeding* Loss of blood from any site or etiology
Assessed by Evidence of bleeding AND symptoms that may  include tachycardia,
hypotension, diaphoresis, lethargy, pallor, cyanosis, shock AND Anemia (low hemoglobin
or  hematocrit)
Suggested outcome
Anemia* Hematocrit or hemoglobin concentration below the lower limit of normal range for
gestational age and post-natal age
Suggested outcome
Polycythemia Hematocrit or hemoglobin concentration above the upper limit of normal range for
gestational age and post-natal age
Taskforce key term
Thrombocytopenia* Platelet count below the lower limit of normal range for gestational age and post-natal age
(BC)f
Suggested outcome
Leukopenia Decreased white blood cell count below lower limit of normal range for gestational and
post-natal age
Taskforce key term
Leukocytosis* Increased white blood cell count above upper limit of normal range for gestational and
post-natal age
Suggested outcome
Coagulopathy
S:  DIC Disseminated
intravascular coagulation
Bleeding and/or clotting disorder associated with abnormal activation of coagulation
pathways
Taskforce key term
Gastrointestinal
Difﬁculty  feeding* Poor suck and/or inability to maintain adequate oral intake for age Suggested outcome
Vomiting Reﬂexive act of ejecting stomach contents through the mouth Taskforce key term
Diarrhea  Increase in frequency and/or change in consistency (liquid) of stools for age (BC)g Taskforce key term
Necrotizing enterocolitis Disease of the gastrointestinal tract characterized by mucosal or transmural necrosis of
the  intestine.
Taskforce key term
Jaundice/
Hyperbilirubinemia*
Elevation of Total and/or Direct–Indirect bilirubin for gestational and post-natal age
Subgroups:
Physiologic hyperbilirubinemia
Neonatal hyperbilirubinemia
Direct/Conjugated hyperbilirubinemia
Indirect/Unconjugated hyperbilirubinemia
Breastfeeding Jaundice
Suggested outcome
Hepatic dysfunction Elevation of liver enzymes and/or coagulopathy Taskforce key term
Metabolic
Hypoglycemia Low serum glucose concentration (mg/dL) below lower limit of normal for gestational and
post-natal age
Taskforce key term
Hypocalcemia/
Hypercalcemia
Concentration of serum (mg/dL) or ionized Calcium below or above the lower and upper
limits of normal for gestational and post-natal age
Taskforce key term
Hypomagnesemia/
Hypermagnesemia
Concentration of serum (meq/L) magnesium below or above the lower and upper limits of
normal for gestational and post-natal age
Taskforce key term
Renal
Renal  insufﬁciency Decreased urinary output and/or elevation of serum creatinine above upper limit of
normal for gestational and post-natal age
Taskforce key term
Renal  failure Persistent oliguria or anuria with decreased creatinine clearance for gestational and
post-natal age
Taskforce key term
Electrolyte anomalies (Na,
K)
Concentration of serum (meq/L) sodium or potassium below or above the lower and upper
limits of normal for gestational and post-natal age
Taskforce key term
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Table 2 (Continued)
Term/synonyms Concept deﬁnition Prioritization
Other
Birth trauma or injury Neonatal injury associated with delivery
Assessed by physical exam AND birth history
Taskforce key term
Allergic  conditions* Infant allergic disorders Suggested outcome
Autoimmune disorders* Maternal and infant autoimmune disorders Suggested outcome
Infant  Immunity* Effect of maternal antibodies on infant responses to active vaccination and/or natural
infection
Effect of maternal antibodies on infant reactogenicity after active vaccination
Suggested outcome
Gender  speciﬁc events* Infant events related to gender Suggested outcome
Sources of Accepted Deﬁnitions: WHO: World Health Organization; BC: Brighton Collaboration; NCS: National Children’s Study; CTCAE: Common Terminology Criteria for
Adverse  Events (National Institutes of Health); NICHD: National Institute of Child Health and Human Development.
* BC-WHO Consultation consensus term.
a See Brighton deﬁnition: Michael Marcy, S., et al., Fever as an adverse event following immunization: case deﬁnition and guidelines of data collection, analysis, and
presentation. Vaccine, 2004. 22(5–6): p. 551–6.
b See Brighton Deﬁnition: Jorch, G., et al., Unexplained sudden death, including sudden infant death syndrome (SIDS), in the ﬁrst and second years of life: case deﬁnition
and  guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007. 25(31): p. 5707–16.
c See Brighton deﬁnition: Bonhoeffer, J., et al., Generalized convulsive seizure as an adverse event following immunization: case deﬁnition and guidelines for data collection,
analysis, and presentation. Vaccine, 2004. 22(5–6): p. 557–62.
d See Brighton deﬁnition: Tapiainen, T., et al., Aseptic meningitis: case deﬁnition and guidelines for collection, analysis and presentation of immunization safety data.
Vaccine, 2007. 25(31): p. 5793–802.
e See Brighton deﬁnition: Sejvar, J.J., et al., Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case deﬁnitions and guidelines for collection, analysis,
and  presentation of immunization safety data. Vaccine, 2007. 25(31): p. 5771–92.
f See Brighton deﬁnition: Wise, R.P., et al., Thrombocytopenia: case deﬁnition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine,
2007.  25(31): p. 5717–24.
g See Brighton deﬁnition: idudu, J., et al., Diarrhea: case deﬁnition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2010.
29(5):  p. 1053–71.
Table 3
Consensus recommendations to further improve safety monitoring of immunization in pregnancy programs.
There is a need for standardized case deﬁnitions for an exhaustive set of events. Until these become available, interim deﬁnitions should be made available
and  shared for widest possible use
The phrase “key terms” could be used rather than “adverse events” or “events of special interest” given their respective regulatory implications
Brighton Collaboration provides an open global platform and mechanisms to lead efforts of deﬁnition standardization given their previous work on
standardizing case deﬁnitions at an international level and their expertise on consensus building
An  overall evaluation framework should be developed:
a. A public consultation should be implemented for review and feedback on the outputs of the meeting
b.  Interim case deﬁnitions should be evaluated at least regarding usefulness, applicability, and reduction of inter-rater variability
c.  Implementation in simple observational studies (e.g., incidence rate studies) should be pursued and to allow for assessment of applicability and positive
predictive values of the deﬁnitions and usefulness of terminologies, guidance and tools
d.  Case deﬁnitions could be incorporated into NIH toxicity tables and tested in clinical trials
Tools should be developed to facilitate implementation at various levels and may  include:
a.  A data collection tool, such as a case report form/data collection list
b.  A glossary of enabling terms
c. Ontologies of the terms, keeping multilingual data collection in mind
d.  Disease code mapping for key events should be performed to support case identiﬁcation
There is a need for guidance(s) for harmonized collection, analysis, and presentation of data in prospective and retrospective data ascertainment
Guidelines should be shared with various stakeholder groups for review and comment
a.  This should be done as part of focused stakeholder consultations
b.  The Council for International Organizations of Medical Sciences (CIOMS) is considering the establishment of a dedicated working group on immunization
in  pregnancy which may  review and potentially recommend the use of standardized case deﬁnitions, guidelines, and tools. The existing CIOMS vaccine
pharmacovigilance working group may  be able to include the topic with review of the Brighton Collaboration case deﬁnitions in their next work plan
starting 2017
Population-based health care data sources should be identiﬁed and incidence rates of key outcomes should be determined (even if outcome deﬁnitions differ
from  those developed by this group) with a particular focus on LMIC while using advanced databases as benchmarks
The  utility of identiﬁed databases in LMIC for observational studies including incidence rate, signal substantiation, and hypothesis testing studies should be
assessed
Ideally, background rates of key events should be established that are country-speciﬁc or site-speciﬁc while using common deﬁnitions. In practice, this is
limited by lack of resources and capacity constraints
Optimal models for conducting post-licensure association studies in LMIC should be assessed including comparison of data collection methods, approaches to
meta-analysis and pooling, and performance evaluation of comparative analytic methods to inform interpretation of results from real concerns
Dissemination strategies should be considered
a. The meeting report should be circulated to all participants and for dissemination to their respective institutions
b.  Participants should raise awareness of this and subsequent efforts within their institutions and professional networks
c.  The two Taskforces should ﬁnalize work and publish concepts
d. Brighton Collaboration should make the terms, disease concepts, interim case deﬁnitions, guidance, and tools via a dedicated resource platform at its
website for immediate use by interested parties
e.  Funders should be informed about this ongoing process so that they can inform their investigators about the process and availability of interim case
deﬁnitions
The  Global Advisory Committee on Vaccine Safety (GACVS) is WHO’s principal advisory body on vaccine safety issues. The committee acknowledged the
development of global standards for vaccine safety monitoring by the current initiative. Their further endorsement will be critical for acceptance and
sustainability of any recommended guidelines and standards
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ncouraged increasing information exchange and collaboration,
hile minimizing duplication of efforts.
The harmonization exercise and consultancy also helped foster
iscussion on the necessary way forward given current limitations.
he participants identiﬁed additional obstacles and needs. Recom-
endations included the development of tools to standardize and
ncrease the efﬁciency of safety data collection in clinical trials and
bservational studies. Further, robust data on background rates
f key events related to immunization in pregnancy, and pooled
afety analyses based on international data sharing would better
nform decision making on maternal immunization programs, and
nhance patient, regulator, and provider decision making and com-
ort with vaccination offered to protect pregnant women and their
hildren from preventable diseases and possible death.
Maternal immunization is an evolving ﬁeld, and adaptation of
tandards and tools to speciﬁc vaccines, protocols, populations,
eographic regions, and other factors is necessary when evaluat-
ng the safety of vaccines in pregnancy. The Brighton Collaboration
as established a collaborative network dedicated to address this
ontinuing need: the Global Alignment of Immunisation Safety
ssessment in Pregnancy (GAIA) [63,64]. The aim of the GAIA
roject is to provide standards and tools to establish a globally
hared understanding of outcomes and approaches to monitor-
ng them with speciﬁc focus on low- and middle-income countries
eeds and requirements. GAIA will build on the efforts of this ini-
ial work and develop standardized case deﬁnitions for selected
ey terms through the standard Brighton process as well as guid-
nce and tools harmonizing data collection in clinical trials and
bservational studies.
The process described in this paper outlines a format suc-
essfully initiating active discussion and sharing of information
etween stakeholders and investigators in view of rapidly evolving
mmunization programs of pregnant women. This approach could
erve as a model for future efforts aiming at early harmonization
f the safety assessment of speciﬁc vaccines and global immuniza-
ion programs leading to sustainable collaboration and concerted
ction while minimizing fragmentation and duplication of efforts
n line with the Global Vaccine Safety Blueprint, the strategic plan
f the WHO  Global Vaccine Safety Initiative [65].
. Disclaimer
Philipp Lambach and Justin Ortiz work for the World Health
rganization. The authors alone are responsible for the views
xpressed in this publication. The ﬁndings, opinions, and assertions
ontained in this document are those of the individual scientiﬁc
rofessional contributors. They do not necessarily represent the
fﬁcial positions of each contributor’s organization (e.g., govern-
ent, university, or corporation). Speciﬁcally, the ﬁndings and
onclusions in this paper are those of the authors and do not nec-
ssarily represent the views of the author’s organizations.
onﬂict of interest statement
There is no conﬂict of interest for this work.
cknowledgements
This work was funded by the World Health Organization. The
uthors are grateful for the invaluable review and suggestions
y the WHO  Consultation participants both during the in person
onsensus meeting as well as on this manuscript: Narendra K.
rora, Ulf Bergman, Niranjan Bhat, Jan Bonhoeffer, Joseph S. Bresee,
im Buttery, Romano Nkumbwa Byaruhanga, Clare Cutland, Frank
estefano, Abdoul Esteghamati, Yirgu Gebrehiwot, Kari Johansen,
[
[3 (2015) 6441–6452 6451
Brigitte Keller-Stanislawski, Sonali Kochhar, Barbara Law, Jerker Lil-
jestrand, Mirjana Nesin, Sten Olssen, Saad Omer, Michael Pﬂeiderer,
Jeffrey Roberts, Craig Rubens, Ajoke Sobanjo-Ter Meulen, James
Southern. The authors wish to thank Melinda Wharton with her
advice planning the taskforce and consultation process. The authors
also acknowledge the contributions of the Maternal and Neonatal
Taskforce members: Maternal taskforce: Maurice Bucagu (WHO),
Yirgu Gebrehiwot (Ethiopian Society of Obstetrics and Gynecology),
Michael G. Gravett (University of Washington), Jerker Liljestrand
(URC), Alexandra Mangili (Novartis Vaccines and Diagnostics), Mir-
jana Nesin (US National Institutes of Health), Jeff Roberts (US
Federal Drug Administration), Milagritos D. Tapia (University of
Maryland). Neonatal taskforce: Narendra K. Arora (INCLEN Trust),
Niranjan Bhat (PATH), Jim P. Buttery (Monash University), Claire L.
Cutland (University of Witwatersrand), Debbie S Gipson (Univer-
sity of Michigan), Paul T. Heath (St George’s University of London),
Sonali Kochhar (JSI), Craig E. Rubens (University of Washington),
Susanne J. Serruya (Latin American Center for Perinatology, Women
and Reproductive Health).
References
[1] Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to
decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis
2013;26:248–53.
[2] WHO. Maternal and neonatal tetanus elimination (MNTE) initiative.
WHO; 2014. Available from: 〈http://www.who.int/immunization monitoring/
diseases/MNTE initiative/en/index.html〉, (accessed July, 2014).
[3] Centers for Disease Control and Prevention. Prevention and control of inﬂuenza
with vaccines. Recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR  2010;59:1–62.
[4] Public Health England. Inﬂuenza. In: The green book; 2012. Available at:
〈https://www.gov.uk/government/uploads/system/uploads/attachment data/
ﬁle/224775/JCVI-statement-on-the-annual-inﬂuenza-vaccination-
programme-25-July-2012.pdf〉 (chapter 19).
[5] Advisory Committee on Immunization Practices (ACIP). Updated recommen-
dations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis vaccine (Tdap) in pregnant women—ACIP 2012. MMWR  2013;62(Feb
(7)):131–5.
[6] Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al.
Effectiveness of maternal pertussis vaccination in England: an observational
study. Lancet 2014;384(9953):1521–8. Oct 25.
[7] National Institutes of Health. Clinical trials. National Institutes of Health; 2015.
Available at 〈http://www.clinicaltrials.org〉 (accessed March 21, 2015).
[8] Bonhoeffer J, Kohl K, Chen RT, Duclos P, Heijbel H, Heininger H, et al., The
Brighton Collaboration. Standardized case deﬁnitions of adverse events fol-
lowing immunization (AEFI). Vaccine 2004;22:547–50.
[9] Brighton Collaboration Guidelines for Data collection in Maternal and Neonatal
Vaccine Trials. 〈https://brightoncollaboration.org/public/what-we-do/setting-
standards/guidelines.html〉.
10] Beigi RH, Goldkind SF, Jevaji I. Research on vaccines and antimicrobials during
pregnancy: challenges and opportunities. Vaccine 2013;31:4261–3.
11] Munoz FM,  Shefﬁeld JS, Beigi RH, et al. Research on vaccines during pregnancy:
protocol design and assessment of safety. Vaccine 2013;31:4274–9.
12] Shefﬁeld JS, Munoz FM,  Beigi RH, et al. Research on vaccines during preg-
nancy: reference values for vital signs and laboratory assessments. Vaccine
2013;31:4264–73.
13] Munoz FM,  Weisman LE, Read JS, Siberry G, Kotloff K, Friedman J, et al.
Assessment of safety in newborns of mothers participating in clinical tri-
als  of vaccines administered during pregnancy. Clin Infect Dis 2014;59(S7):
S415–28.
14] Beigi RH, Fortner KB, Munoz FM,  Roberts J, Gordon JL, Han HH, et al. Mater-
nal  immunization: opportunities for scientiﬁc advancement. Clin Infect Dis
2014;59(S7):S408–14.
15] World Health Organization Weekly Epidemiological Record, Vaccines against
inﬂuenza WHO  position paper – November 2012, WER  No. 47, 2012, 87, 461-
476,  Available at: 〈http://www.who.int/wer〉.
16] World Health Organization. Meeting of the Strategic Advisory Group of experts
on immunization, November 2013—conclusions and recommendations. Vacci-
nation of pregnant and lactating women. Wkly Epidemiol Rec 2014;89:1–20.
Available at: 〈http://www.who.int/wer〉 (WER No. 1).
17] World Health Organization. Revised guidance on the choice of pertussis vac-
cines: July. Wkly Epidemiol Rec 2014;89(Jul (30)):337–40 (2014).18] Zaman K, et al. Effectiveness of maternal inﬂuenza immunization in mothers
and infants. N Engl J Med  2008;359:1155–64.
19] Madhi SA, Cutland CL, Kuwanda L, Weingberg A, Hugo A, Jones S, et al. Inﬂuenza
vaccination of pregnant women and protection of their infants. N Engl J Med
2014;371:918–31.
6 ccine 3
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[452 F.M. Munoz et al. / Va
20] Fulton TR, et al. A systematic review of adverse events following immu-
nization during pregnancy and the newborn period. Vaccine 2015;33:
6453–65.
21] WHO  and Brighton Collaboration Consultative Meeting Report, available at:
〈http://www.who.int/immunization/research/meetings workshops/brighton
keyterms safety pregnancy.pdf?ua=1〉.
22] World Health Organization (WHO). AE deﬁnitions. Wkly Epidemiol Rep
2014;89(1):1–20. Available at: 〈www.who.org〉.
23] World Health Organization. Global manual on surveillance of adverse events
following immunization (AEFI). In: Draft 2.0; Feb, 2014.
24] Global Advisory Committee on Vaccine Safety. The safety of immunization
during pregnancy. Wkly Epidemiol Rep 2013;88(July):301–12 (June 2013, no.
29).
25] World Health Organization, Department of Making Pregnancy Safer. Family and
community health, WHO. 〈www.who.int/making pregnancy safer〉.
26] World Health Organization. In: Howson CP, Kinney MV,  Lawn JE, editors. The
global action report on preterm birth. Geneva: World Health Organization;
2012 (March of Dimes, PMNCH, Save Children, WHO. Born too Soon).
27] National Institutes of Health (NIH) Division of AIDS (DAIDS). Table for grading
the  severity of adult and pediatric adverse events (Version 1.0 Dec 2004,
Clariﬁcation August 2009; and Version 2.0 Draft May  2013); 2014. Available
at: 〈http://rsc.tech-res.com/document/safetyandpharmacovigilance/table for
grading severity of adult pediatric adverse events.pdf〉  (accessed 29 May
2014).
28] National Institutes of Health (NIH) Division of Microbiology and Infectious Dis-
eases (DMID). Pediatric toxicity tables. Draft; November, 2007. 〈http://www.
niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/
dmidpedtox.pdf〉 (accessed 29 May  2014).
29] National Children Study Terminology, 2014. available at: 〈http://evs.nci.
nih.gov/ftp1/nichd/〉  (accessed July, 2014).
30] NICHD. Maternal–fetal medicine units (MFMU) network; 2014. Available at:
〈https://www.nichd.nih.gov/research/supported/Pages/mfmu.aspx〉 (accessed
29  May 2014).
31] Research Triangle Institute, NICHD. Neonatal research network; 2014. Available
at: 〈https://neonatal.rti.org/about/network.cfm〉 (accessed 29 May  2014).
32] Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) An initiative
of  Seattle Children’s Hospital, Research and Foundation, 2014. Available at:
〈http://gapps.org/〉  (Accessed 02 June 2014).
33] GAVI Alliance. GAVI’s mission; 2014. Available at: 〈http://www.gavialliance.
org/about/mission/〉 (Accessed 02 June 2014).
34] UNICEF. United States fund; 2014. Available at: 〈http://www.unicefusa.org/〉
(accessed 02 June 2014).
35] World Health Organization (WHO). Health topics: maternal health; 2014. Avail-
able  at: 〈http://www.who.int/topics/maternal health/en/〉 (accessed 02 June
2014).
36] Souza JP, Gulmezoglu AM,  Vogel J, Carroli G, Lumbiganon P, Qureshi Z, et al.
Moving beyond essential interventions for reduction of maternal mortality (the
WHO  Multicountry survey on maternal and newborn health): a cross sectional
study. Lancet 2013;381:1747–55.
37] Kasenbaum N, Bertozzi-Villa A, Coggeshall MS,  et al. Global, regional, and
national levels and causes of maternal mortality during 1990–2013: a
systematic analysis for the Global Burden of Disease Study 2013. Lancet
2014;2(May):1014 (epub).
38] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for
the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.
39] Lawn JE, Blencove H, Pattison R, Causens S, Kumar R, Ibiebele I, et al. Still-
births: where? When? Why? How to make the data count? Lancet 2011;377:
1448–63.
40] Lawn JE, Lee ACC, Kinney M,  Sibley M,  Carlo AW,  Paul V, et al. Two million
intrapartum related stillbirths and neonatal deaths: where, why and what can
be  done? Int J Gynecol Obstet 2009;107:S5–19.
41] International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) published by the U.S. Public Health Service and Health Care Finan-
cing Administration, available at: 〈http://www.cms.gov/index.html〉.
42] International Classiﬁcation of Diseases, Tenth Revision, Clinical Modiﬁcation
(ICD-10-CM) published by the U.S. Public Health Service and Health Care Finan-
cing Administration, available at: 〈http://www.cms.gov/index.html〉.
[
[3 (2015) 6441–6452
43] US Department of Health and Human Services, National Institutes of Health
and National Cancer Institute. Common terminology criteria for adverse events
(CTCAE). Version 4.0; 2009 (Published May  28, 2009 (v4.03:June 14, 2010)).
44] Medical Dictionary for Regulatory Activities (MeDRA).Medical Dictionary for
Regulatory Activities (MeDRA) of the international conference on harmonisa-
tion  of technical requirements for registration of pharmaceuticals for human
use  (ICH). 2015. Accessible at: 〈http://www.meddra.org/〉 (accessed July 24,
2015).
45] Eurocat Garne, Ester. EUROCAT report: developing the surveillance of multiple
congenital anomalies; 2014.
46] EUROCAT. Coding of Anomalies. Available at: 〈www.eurocat-network.eu/
newprevdata/appendices.cgi〉.
47]  EUROCAT. EUROCAT syndrome guide. Deﬁnition and coding of syndromes;
2004. Available at: 〈www.eurocat.ulster.ac.uk〉 (revised 2008).
48] Loane M,  Dolk H, Garne E, Greenlees R, EUROCAT Working Group. Paper 3.
EUROCAT data quality indicators for population based registries of congenital
anomalies. Birth Defects Res (A) 2011;91:S23–30.
49] Wellesley D, Boyd P, Dolk H, Pattenden S. An etiological classiﬁcation of birth
defects for epidemiological research. J Med  Genet, Vol 42, No.1, pp 54–57.
Available at: 〈http://www.eurocat.ulster.ac.uk/pubdata/〉.
50] Metropolitan Atlanta Congenital Defects Program (MACDP) Birth defects. Avail-
able  from: 〈http://www.cdc.govncbddd/birthdefects/macdp.html〉.
51] National Birth Defects Prevention Network. Birth defects surveillance guide-
lines. Available at: 〈http://www.nbdpn.org/birth defects surveillance gui.
php〉.
52] International Birth Defects Information Systems. Website: 〈http://www.ibis-
birthdefects.org/〉.
53] International Clearinghouse for Birth Defects Surveillance and Research. Web-
site: 〈http://www.icbdsr.org〉.
54] World Health Organization (WHO), National Center on Birth Defects and
Developmental Disabilities from the United States Centers for Disease Con-
trol and Prevention (CDC), International Clearinghouse for Birth Defects
Surveillance and Research (ICBDSR). Birth defects surveillance: a manual for
programme managers. Geneva: World Health Organization; 2014. Available
at: 〈http://www.who.int/nutrition/publications/birthdefects manual/en/〉.
55] Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classiﬁca-
tion for the National Birth Defects Prevention Study. Birth Defects Res (A)
2003;67:193–201.
56] Council for International Organizations of Medical Services (CIOMS), World
Health Organization (WHO). Deﬁnition and application of terms for vaccine
pharmacovigilance. In: Report of CIOMS/WHO working group on vaccine phar-
macovigilance; 2012. Available at: 〈http://whglibdoc.who.int/publications/
2012/9789290360834 eng.pdf〉.
57] CDC. Vaccine safety. In: Clinical immunization safety assessment (CISA) project;
2014. Available at: 〈http://www.cdc.gov/vaccinesafety/activities/cisa.html〉
(accessed 29 May 2014).
58] The Vaccine Adverse Event Reporting System (VAERS), 2015. Available at:
〈https://vaers.hhs.gov/index〉, (accessed July 24, 2015).
59] Martin JA, Hamilton BE, Ventura JS, Osterman MJK, Wilson AC, Mathews TJ, The
Division of Vital Statistics. Births: ﬁnal data for 2010. National vital statistics
reports of the Centers for Disease Control and Prevention, vol. 61; August, 2012
(No. 1).
60] Hamilton BE, Martin JA, Osterman MJK, Curtin SC, The Division of Vital Statis-
tics.  Births: preliminary data for 2013. National vital statistics report of the
Centers for Disease Control and Prevention, vol. 63; May, 2014. Available at:
〈http://www.cdc.gov/nchs/data/nvsr/nvsr63/〉  (No. 2).
61] American College of Obstetrics and Gynecology. Practice bulletins; 2014. Avail-
able at: 〈http://www.acog.org〉 (accessed 23 July, 2014).
62] American College of Obstetrics and Gynecology. reVITALize deﬁnitions; 2014.
Available at: 〈http://www.ACOG.org〉, (accessed 23 July, 2014).
63] Brighton Collaboration Resources, 2015. Website available at: 〈http://
brightoncollaboration.org/public/resources/standards/case-deﬁnitions/
pregnancy.html〉 (accessed April 25, 2015).64] GAIA Consortium Website, 2015, Available at: 〈http://gaia-consortium.net〉,
(accessed May  30, 2015).
65] Maure CG, Dodoo AN, Bonhoeffer J, Zuber PLF. The global vaccine safety ini-
tiative: enhancing vaccine pharmacovigilance capacity at country level. Bull
World Health Organ 2014;92(9):695–6.
